Aussie8 – Lifestyle
Author:
Pliant Therapeutics, Inc.
Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference
May 6, 2026
Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors
April 30, 2026
Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting
April 18, 2026
Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting
March 18, 2026
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results
March 11, 2026